Ablynx has been granted a patent for immunoglobulin single variable domains that bind GITR, enhancing immune response and inhibiting tumor growth. The polypeptides consist of specific sequences that target GITR with high affinity, offering potential for prophylactic, therapeutic, or diagnostic use in pharmaceutical compositions. GlobalData’s report on Ablynx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Ablynx NV - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ablynx, was a key innovation area identified from patents.

Inhibiting tumor growth by administering polypeptides binding gitr

Source: United States Patent and Trademark Office (USPTO). Credit: Ablynx NV

A recently granted patent (Publication Number: US11919966B2) discloses a method for inhibiting tumor growth by administering a pharmaceutically active amount of at least one polypeptide containing an immunoglobulin single variable domain (ISVD) that specifically binds to glucocorticoid-induced TNFR family-related receptor (GITR) with high affinity. The binding of the ISVD to GITR enhances an immune response, with specific sequences outlined for the framework regions and complementarity determining regions of the ISVD. The method involves the administration of the polypeptide as a pharmaceutical composition, potentially combined with other groups or residues to increase its half-life.

Furthermore, the patent extends the application of the method for the treatment of cancer, targeting various types such as squamous cell cancer, lung cancer, melanoma, kidney cancer, glioblastoma, prostate cancer, and many others. The method can be combined with chemotherapy, radiation therapy, cancer vaccines, or other therapeutic agents to enhance its efficacy. Additionally, the patent lists a range of additional therapeutic agents that can be used in conjunction with the ISVD-containing polypeptide, including immune checkpoint inhibitors like PD-1, PD-L1, and CTLA-4, as well as various other immune modulators and receptors to target cancer cells effectively.

To know more about GlobalData’s detailed insights on Ablynx, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies